Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses.

Monica Saumoy,Devika Gandhi,Seth Buller,Shae Patel,Yecheskel Schneider,Gregory Cote,Michael L Kochman,Nikhil R Thiruvengadam,Reem Z Sharaiha

Gut（2023）

引用 0|浏览10

暂无评分

摘要

Cost-effective strategies were: ESG for class I obesity and SG for class II/III obesity. Semaglutide may be cost-effective with substantial cost reduction. Given potentially higher utilisation rates with pharmacotherapy, semaglutide may provide the largest reduction in obesity-related mortality.

查看译文

关键词

obesity, gastrointestinal surgery, gastrectomy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要